Abstract: Bridged heterocyclyl-substituted pyrimidine compounds, a preparation method and medical use thereof. The compounds or pharmaceutical compositions comprising same can be used as JAK1 and TYK2 kinase inhibitors for treating JAK1 and TYK2 kinase activity-related diseases such as inflammations, autoimmune diseases and cancers.

Abstract: A tricyclic compound having the structure represented by general formula (I), a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the prevention and treatment of a variety of diseases caused by toxic aldehydes.

Abstract: The present invention relates to pyrrolo-aromatic heterocyclic compounds, a preparation method therefor and medical use thereof. Particularly, the present invention relates to a compound represented by formula I, a preparation method therefor, a pharmaceutical composition comprising the compound, and use of the compound as a BTK kinase inhibitor. The compound and the pharmaceutical composition comprising same can be used for the treating diseases associated with BTK kinase activity, such as inflammations, autoimmune disorders, and cancers. The definition of each substituent in formula I is the same as that in the description.

Abstract: Disclosed are a tricyclic compound as represented by general formula (I), a pharmaceutical composition containing same, and a preparation method therefor and the medical use thereof. The compound can be used for preventing and treating a variety of diseases caused by toxic aldehydes.

Abstract: A bridged heterocyclyl-substituted pyrimidine compound, a preparation method therefor, and pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method for the compound, a pharmaceutical composition containing the compound, use of the compound as a JAK1 and TYK2 kinase inhibitor, and use in treating diseases related to JAK1 and TYK2 kinase activity, such as inflammations, autoimmune diseases, and cancers. The definition of each substituent in general formula (I) is the same as that in the description.

Abstract: The present invention relates to aromatic ring or heteroaromatic ring compounds, a preparation method therefor and a medical use thereof. Particularly, the present invention relates to a compound as shown in general formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound and a use thereof as an agonist for a farnesoid X receptor (FXR). The compound and the pharmaceutical composition comprising the compound can be used for treating and/or preventing FXR activity-related diseases, for example, cholestatic symptoms, diabetes and complications thereof, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatosis heptitis (NASH), obesity or metabolic syndrome (diseases associated with dyslipidemia, diabetes, abnormally high body weight index), cardiovascular diseases and so on. The definition of each substituent in the general formula (I) is the same as that in the description.

Abstract: The present invention relates to a spiro compound and medical uses thereof. Specifically, the present invention relates to a spiro compound represented by the general formula (I), a preparation method thereof, a pharmaceutical composition containing the same, and is used as an acetyl-Coenzyme A carboxylase (ACC) inhibitor and is used for treating diseases associated with ACC activity. Each substituent in the general formula (I) is as defined in description.

Abstract: The present invention relates to pyrrolo-aromatic heterocyclic compounds, a preparation method therefor and medical use thereof. Particularly, the present invention relates to a compound represented by formula I, a preparation method therefor, a pharmaceutical composition comprising the compound, and use of the compound as a BTK kinase inhibitor. The compound and the pharmaceutical composition comprising same can be used for the treating diseases associated with BTK kinase activity, such as inflammations, autoimmune disorders, and cancers. The definition of each substituent in formula I is the same as that in the description.

Abstract: The present invention belongs to the pharmaceutical field, and relates to a preparation method for a series of benzimidazole derivatives, their pharmaceutical salts and pharmaceutically acceptable prodrugs, a pharmaceutical composition containing the derivatives, and the uses of the derivatives and pharmaceutical composition in the preparation of antigout drugs and in the treatment of related diseases.

Abstract: The present invention belongs to the pharmaceutical field, and relates to a preparation method for a series of benzimidazole derivatives, their pharmaceutical salts and pharmaceutically acceptable prodrugs, a pharmaceutical composition containing the derivatives, and the uses of the derivatives and pharmaceutical composition in the preparation of antigout drugs and in the treatment of related diseases.